Vitamin B12 deficiency can cause prolonged jaundice in newborns by disrupting red blood cell production and increasing bilirubin levels. According to Gram Research analysis, a 2026 study of 103 infants found that sublingual methylcobalamin treatment raised B12 levels from an average of 139 ng/L to 657 ng/L within 1.5 months, effectively treating jaundice without injections. This non-invasive approach offers a practical alternative to traditional B12 injections for affected babies.
Newborns with prolonged jaundice—a yellowing of the skin that lasts longer than expected—may have a vitamin B12 deficiency. According to Gram Research analysis, a new study of 103 babies found that sublingual methylcobalamin (a form of B12 given under the tongue) effectively treated jaundice caused by low B12 levels. The treatment raised B12 levels significantly within 1.5 months and proved to be a non-invasive alternative to injections. This finding is important because it offers parents and doctors a simpler treatment option for a condition that can affect newborn health.
Key Statistics
A 2026 cross-sectional study of 103 newborns with prolonged jaundice found that sublingual methylcobalamin treatment increased vitamin B12 levels nearly 5-fold, from an average of 139 ng/L before treatment to 657 ng/L after 1.5 months.
In the same study, babies receiving B12 injections showed more modest improvements, with B12 levels rising from 166 ng/L to 503 ng/L at 1.5 months, suggesting sublingual treatment may achieve faster peak B12 restoration.
Research reviewed by Gram found that vitamin B12 deficiency was identified in 103 infants presenting with prolonged neonatal jaundice, demonstrating that B12 deficiency is a clinically significant but potentially underdiagnosed cause of prolonged jaundice in newborns.
The Quick Take
- What they studied: Whether giving babies vitamin B12 under the tongue (sublingual methylcobalamin) could treat prolonged jaundice caused by B12 deficiency, compared to traditional B12 injections.
- Who participated: 103 newborns with prolonged jaundice and confirmed vitamin B12 deficiency (blood levels below 250 ng/L). The babies were about 5 weeks old on average when diagnosed. 72 received sublingual B12 treatment, and 31 received B12 injections.
- Key finding: Babies receiving sublingual B12 showed dramatic improvement: their B12 levels jumped from an average of 139 ng/L before treatment to 657 ng/L after 1.5 months—nearly a 5-fold increase. The injection group also improved but with slightly lower peak levels (503 ng/L).
- What it means for you: If your newborn has prolonged jaundice, doctors should test for vitamin B12 deficiency. If present, sublingual B12 offers an effective, non-invasive treatment option that doesn’t require injections. However, this study was observational, so more research is needed before making widespread treatment changes.
The Research Details
Researchers conducted a descriptive cross-sectional study, meaning they observed and compared two groups of babies at specific points in time rather than randomly assigning them to treatments. They studied 103 infants with prolonged jaundice at a pediatric hospital in Turkey. All babies had confirmed vitamin B12 deficiency (blood levels below 250 ng/L). The babies were divided into two groups: 72 received sublingual methylcobalamin (B12 placed under the tongue), and 31 received intramuscular cyanocobalamin (B12 injections into muscle). Researchers measured vitamin B12 blood levels before treatment, at 1.5 months, and at 3 months to see how well each treatment worked.
This study design allows doctors to see real-world treatment outcomes in actual patients. By comparing two different treatment approaches in the same setting, researchers could evaluate whether the non-invasive sublingual method works as well as the traditional injection method. This matters because parents and doctors prefer simpler treatments when they’re equally effective.
This is a descriptive cross-sectional study, which is a lower level of evidence than randomized controlled trials. The study wasn’t randomized, meaning doctors chose which treatment each baby received rather than assigning treatments randomly. This can introduce bias. However, the study provides real-world data from a hospital setting with clear measurements of B12 levels. The sample size of 103 babies is reasonable for this type of study. The main limitation is that we can’t be certain the sublingual treatment caused the improvement without a randomized comparison.
What the Results Show
Babies receiving sublingual methylcobalamin showed impressive B12 level increases. Before treatment, their average B12 level was 139 ng/L. After 1.5 months of sublingual treatment, levels jumped to 657 ng/L—nearly a 5-fold increase. By 3 months, levels settled to 394 ng/L, which is still well above the deficiency threshold. Babies receiving injections also improved: their B12 levels went from 166 ng/L before treatment to 503 ng/L at 1.5 months, then to 346 ng/L at 3 months. Both groups showed significant improvement, though the sublingual group had higher peak levels at 1.5 months. The sublingual treatment was non-invasive, meaning no needles were required, which is important for infant comfort and parent acceptance.
The study included roughly equal numbers of boys and girls in both treatment groups, suggesting the condition affects both sexes similarly. All babies were born at full term (around 38-39 weeks gestation), indicating this isn’t a problem limited to premature infants. The average age at diagnosis was about 5 weeks, showing that B12 deficiency jaundice typically appears in the first month of life. Both treatment groups had similar baseline characteristics, making the comparison between treatments more reliable.
This research adds to growing evidence that vitamin B12 deficiency can cause prolonged jaundice in newborns—a condition that doctors don’t always test for. Previous research has shown that B12 deficiency affects red blood cell production, leading to their breakdown and increased bilirubin (the yellow pigment causing jaundice). This study is among the first to directly compare sublingual B12 treatment to injections in newborns, suggesting that the non-invasive approach may be viable.
This study has several important limitations. It wasn’t randomized, so doctors chose which treatment each baby received based on their own judgment, which could bias results. The study was observational rather than experimental, meaning we can see what happened but can’t prove the treatment caused the improvement. The sample size was relatively small (103 babies), and the study was conducted at a single hospital in Turkey, so results may not apply to all populations. The study didn’t include a control group of untreated babies, so we can’t be certain how much improvement would occur without any treatment. Finally, longer-term follow-up data would help confirm that improvements last.
The Bottom Line
If your newborn has prolonged jaundice (lasting more than 2 weeks), ask your pediatrician to test for vitamin B12 deficiency. If deficiency is confirmed, sublingual methylcobalamin appears to be an effective, non-invasive treatment option. However, this research is preliminary, and treatment decisions should be made with your doctor based on your baby’s specific situation. Confidence level: Moderate—the evidence is promising but comes from a single observational study.
Parents of newborns with prolonged jaundice should care about this research. Pediatricians and neonatologists treating jaundiced infants should consider B12 deficiency testing. This is particularly relevant in populations with higher rates of B12 deficiency, such as those with dietary restrictions or malabsorption issues. This research may be less relevant for babies with jaundice from other causes (like blood type incompatibility or prematurity).
Based on this study, B12 levels improved dramatically within 1.5 months of starting sublingual treatment. Most babies likely saw improvement in jaundice symptoms within this timeframe, though individual variation is expected. Continued monitoring at 3 months showed sustained improvement, suggesting the treatment has lasting effects.
Frequently Asked Questions
Can vitamin B12 deficiency cause jaundice in newborns?
Yes. Vitamin B12 deficiency disrupts red blood cell production, causing them to break down faster and release bilirubin, the yellow pigment that causes jaundice. A 2026 study of 103 infants confirmed this connection, showing that B12 deficiency was associated with prolonged jaundice lasting beyond the typical newborn period.
Is sublingual B12 treatment effective for newborn jaundice?
Research suggests sublingual methylcobalamin is effective. In a study of 72 infants, B12 levels increased nearly 5-fold within 1.5 months of sublingual treatment. However, this was an observational study, so more randomized research is needed to confirm effectiveness compared to other treatments.
How long does it take sublingual B12 to treat jaundice in babies?
According to the 2026 study, significant B12 level improvements appeared within 1.5 months of starting sublingual methylcobalamin treatment. Most babies likely experienced jaundice improvement within this timeframe, though individual variation occurs. Continued improvement was observed at the 3-month follow-up.
Is sublingual B12 better than B12 injections for newborns?
Both treatments improved B12 levels, but sublingual treatment achieved higher peak levels (657 ng/L vs. 503 ng/L at 1.5 months). Sublingual treatment is non-invasive, avoiding needle discomfort. However, the study wasn’t randomized, so definitive conclusions require further research.
What should I do if my newborn has prolonged jaundice?
Contact your pediatrician immediately. Ask them to test for vitamin B12 deficiency, especially if jaundice persists beyond 2 weeks. If deficiency is confirmed, sublingual methylcobalamin appears to be an effective treatment option worth discussing with your doctor.
Want to Apply This Research?
- Track your baby’s skin color daily using a simple photo log (same lighting, same time of day) to monitor jaundice improvement. Also record the date treatment started and any changes in feeding or symptoms.
- If your baby is prescribed sublingual B12, set daily reminders to administer the dose at the same time each day. Log each dose in the app to ensure consistency and track any changes in your baby’s jaundice or energy levels.
- Create a timeline in the app marking treatment start date, 1.5-month follow-up, and 3-month follow-up. Record B12 blood test results when available. Track jaundice severity (mild, moderate, severe) at each visit to correlate with B12 levels and treatment response.
This article summarizes research findings and should not replace professional medical advice. Vitamin B12 deficiency and prolonged jaundice in newborns require diagnosis and treatment by qualified healthcare providers. Do not attempt to treat your baby based on this information alone. Always consult with your pediatrician before starting any treatment, including vitamin supplements. This study was observational and not randomized, so results should be interpreted cautiously. Individual outcomes may vary, and treatment decisions should be personalized based on your baby’s specific medical situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.